Volume 15, Issue 6, Pages (September 2012)

Slides:



Advertisements
Similar presentations
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)— Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication.
Advertisements

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,
Program-Specific Cost-Effectiveness Analysis: Breast Cancer Screening Policies for a Safety-Net Program Joy Melnikow, MD, MPH, Daniel J. Tancredi, PhD,
Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical.
Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.
Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,
Volume 14, Issue 8, Pages (December 2011)
Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual.
Volume 15, Issue 8, Pages (December 2012)
Volume 18, Issue 4, Pages (June 2015)
Volume 18, Issue 5, Pages (July 2015)
Mapping the COPD Assessment Test onto EQ-5D
Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results  Becky Pennington, MSc,
Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-
Volume 17, Issue 2, Pages (March 2014)
Volume 14, Issue 1, Pages (January 2011)
Volume 18, Issue 4, Pages (June 2015)
Volume 15, Issue 1, Pages S20-S28 (January 2012)
Volume 14, Issue 4, Pages (June 2011)
Volume 14, Issue 8, Pages (December 2011)
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Volume 17, Issue 8, Pages (December 2014)
Volume 15, Issue 2, Pages (March 2012)
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Volume 14, Issue 8, Pages (December 2011)
Multidomain Patient-Reported Outcomes of Irritable Bowel Syndrome: Exploring Person-Centered Perspectives to Better Understand Symptom Severity Scores 
Volume 15, Issue 1, Pages (January 2012)
Volume 19, Issue 5, Pages (July 2016)
Volume 17, Issue 2, Pages (March 2014)
Examining the Value of Menopausal Symptom Relief Among US Women
Volume 17, Issue 2, Pages (March 2014)
Volume 19, Issue 6, Pages (September 2016)
Eric Nsiah-Boateng, MPH, Moses Aikins, PhD 
The Development of the Romanian Scorecard HTA System
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
The Update of the Mexican Health Care Formulary and Supply Catalog in the Context of the Health Technology Assessment  Pedro Rizo Ríos, MD, MHSM, Aurora.
Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making 
The Process of Privatization of Health Care Provision in Poland
Ernest Attuquaye Quaye, BPharm, MPH, Edward O
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Cost-Effectiveness Analysis of a Screening Program for Breast Cancer in Vietnam  Lan Hoang Nguyen, Wongsa Laohasiriwong, John Frederick Stewart, Pamela.
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Value in Health Regional Issues
What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.
Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia in Guatemala  Benjamin Cruz Rodriguez, MD, Sergio Leal, MD, Gonzalo Calvimontes,
Cost-Effectiveness of Screening and Treatment for Cervical Cancer in Tanzania: Implications for other Sub-Saharan African Countries  Stephanie Nelson,
The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel 
Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD 
Omneya Mohamed, PhD, David H. Kreling, PhD 
Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M
Value in Health Regional Issues
The Economic Impact of Cigarette Smoking on the Poor in Jordan
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Children Hospitalized for Varicella: Complications and Cost Burden
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand  Panrasri Khonputsa,
Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe,
Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters?  Chun-Ru Chien, MD, PhD, Ya-Chen Tina.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers  Valentina.
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Social Cost of Substance Abuse in Russia
Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD 
Victoria I. Ignatyeva, MPH, Johan L
Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.
Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.
Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD 
Presentation transcript:

Volume 15, Issue 6, Pages 887-893 (September 2012) Orthopaedic Trauma Care in Haiti: A Cost-Effectiveness Analysis of an Innovative Surgical Residency Program  Lucas C. Carlson, BA, Gerard P. Slobogean, MD, MPH, FRCSC, Andrew N. Pollak, MD  Value in Health  Volume 15, Issue 6, Pages 887-893 (September 2012) DOI: 10.1016/j.jval.2012.06.004 Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Cost-effectiveness probability by willingness-to-pay (USD). Value in Health 2012 15, 887-893DOI: (10.1016/j.jval.2012.06.004) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Monte Carlo Simulation: cost and effectiveness outcomes for OTCS program model. DALY, disability-adjusted life-year; WHO-CHOICE, World Health Organization-CHOosing Interventions that are Cost-Effective. Value in Health 2012 15, 887-893DOI: (10.1016/j.jval.2012.06.004) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 One-way sensitivity analyses. The cost-effectiveness ranged from $80 to $260/DALY averted across the ranges of all variables. Value in Health 2012 15, 887-893DOI: (10.1016/j.jval.2012.06.004) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions